A Premier Boutique
Investment Bank

Specializing in PIPEs, Reverse Mergers,
M&A, Private Equity & LP Equity for CRE

Author Archives: admin

Palladium Capital Group Facilitates $5,000,000 Financing for Cryptyde, Inc. (NASDAQ: TYDE)

Post Date: Mar. 15, 2023

NEW YORK, NY – On March 15, 2023, Palladium Capital Group, LLC, acted as sole placement agent for Cryptyde, Inc. for the issuance and sale of a Senior Secured Convertible Note with an initial principal amount of $5,555,000. The purchase price of the Note and the Warrant is $5 million.

Palladium Capital Group Sole Placement Agent for $10,000,000 Private Placement for Vinco Ventures Inc. (NASDAQ:BBIG)

Post Date: Feb. 5, 2023

NEW YORK, NY – On February 5, 2023, Palladium Capital Group, LLC, acted as sole placement agent for Vinco Ventures Inc., in its issuance of a $10,000,000 principal amount convertible note and shares of Series A perpetual non-convertible preferred stock of the Company designated as Series A Preferred Stock.

Palladium Exclusive Placement Agent in $550,000 Debt Financing for PishPosh, Inc.

Post Date: Jan. 31, 2023

NEW YORK, NY, January 31st, 2023 – Palladium Capital Group, LLC, today announces that it has served as the exclusive placement agent and financial advisor to PishPosh Inc. in its issuance of an aggregate of $550,000 in unsecured original issue discount promissory notes.

For more information about PishPosh Baby, please visit their website: https://pishposhbaby.com/pages/about-us

Palladium Serves as Sole Placement Agent for $38,400,000 Financing of Darwin CX

Post Date: Dec. 8, 2022

NEW YORK, NY, December 8th, 2022 – Palladium Capital Group, LLC, today announces that it has served as sole placement agent for Darwin CX (“DCX”) for its $38.4M USD funding. The funding was co-led by Toronto-based First Ascent Ventures and California-based Felicitas Global Partners. Additional funding was provided by New York-based Metropolitan Partners Group and Liam Lynch.

“Darwin is on its ascent to establish itself as the industry leader thanks to our strong culture led by dedicated employees and supportive partners,” said DCX Executive Chairman and lead investor Liam Lynch. “We’re thrilled to add these experienced and savvy B2B SaaS investors led by Richard Black and Tony van Marken at First Ascent Ventures, Bonar Chhay at Felicitas Global Partners, and Max Segal at Metropolitan Partners Group, to propel our next stage of growth.”

“This funding from top-tier investment groups accelerates Darwin’s mission to serve our clients with tools and capabilities to grow their subscriber bases and save up to half of their fulfilment and marketing costs,” said Darwin co-founder and CEO Laas Turnbull. “This funding means we can confidently scale our operations, build strategic channel partnerships, and continue investing in our very ambitious product roadmap, led by Michael Smith, our co-founder, CTO, and Head of Innovation.”

DCX is an industry-leading software-as-a-service platform that leverages real-time data to increase acquisition and retention rates while decreasing marketing spend for publishers and membership-based organizations. It enables data-driven transformations for brands that often have sophisticated requirements for customer acquisition and retention, reporting, and customer service. DCX integrates seamlessly with third-party applications and fulfillment providers. DCX delivers a far superior customer experience compared to the industry’s legacy technology and processes—the driving motivation behind another recent partnership announcement with publishing powerhouse a360 Media.

“Numerous industries that relied on legacy mainframe-based technology—costly and rigid—have been disrupted by cloud-based systems like Darwin,” said Richard Black, co-founder and Managing Partner of First Ascent Ventures. “This partnership will ensure that Darwin’s cloud-based technology will replace the legacy mainframe-based technology still used in the subscription economy.”

DCX has scaled clients by a factor of 10 in the past 18 months, adding new customers and channel partners across North America. Through a mix of organic growth and acquisition, DCX will continue in its drive to become a major voice in the subscription economy, which has grown more than 23% in the past year to $51 billion. By 2025, it is expected to be a $141-trillion economy.

“At Metropolitan, we see a large number of investment opportunities in the lower and middle market—Darwin stands out given its leadership team and growth strategy,” said Metropolitan Vice-President Max Segal. “Partnering with First Ascent Ventures and Felicitas to support Darwin is a winning combination.”

The transaction team was led by Chief of Staff Toby McCoy, CFO Jon Soucy, and General Counsel Chris Bedor at Darwin; Senior Associate Noah Chaikof at First Ascent Ventures; Director Calvin Marks and Associate Cody Odening at Felicitas Global Partners, with support from David McQuaid, Bruce Winans, and Alfonso Alejo at Compass Securities/Palladium Capital Group; Britt Rogers at Akin Gump Strauss Hauer & Feld; Kevin Kilduff at Kilduff Law; Aaron Rothman at K&L Gates; and Rebecca Chilton at Nelson Mullins.

About Darwin CX
Darwin CX is a transformative SaaS platform at the leading edge of the subscription economy serving clients on 3 continents. It helps brands accelerate acquisition and retention—and increase loyalty—through innovative and customized check-out pages, targeted audience offerings, real-time A/B testing, and best-in-class analytics. The Darwin platform enables clients to have complete freedom and control over customer data in order to tailor the best possible customer experiences. Darwin provides a full suite of fulfillment services to its clients through its integrations with direct mail, lettershop, in-bound mail processing, and call center partners.

About Metropolitan
Metropolitan Partners Group is a private investment firm that provides asset-based debt capital to non-sponsored situations in the domestic lower middle market space, unconstrained by industry or asset class. Metropolitan works directly with business owners and management teams to grow their balance sheets and build lasting value with its tailored capital solutions, while aiming to provide downside protection to its investors.

About First Ascent Ventures
Founded in 2015 by Richard Black and Tony van Marken, First Ascent Ventures invests in early-stage, emerging, and growth-oriented enterprise software companies in the information technology sector. The First Ascent Ventures team bring deep bench strength as operating executives and investors having built and invested in significant, global enterprise software companies.

About Felicitas Global Partners
Felicitas Global Partners is an alternatives investment firm that manages portfolios of secondaries, private credit, and private equity investments. Felicitas manages capital from an institutional base of asset management firms, foundations, family offices, and private wealth managers, with approximately $700M Assets Under Management.

For further information: Alea Sarkar, 1-647-400-1455, alea@darwin.cx

Palladium Raises $2,000,000 Equity Round for Hero Scientific Ltd.

Post Date: Aug. 1, 2022

NEW YORK, NY, August 1st, 2022 – Palladium Capital Group, LLC, announces that it has served as the sole placement agent for Hero Scientific Ltd. in its $2,000,000 Equity Round.

For more information about Hero Scientific, please visit their website: https://www.heroscientific.com/

Palladium Capital Group Facilitates Restructuring for Cryptyde, Inc. (NASDAQ: TYDE)

Post Date: Jul. 28, 2022

NEW YORK, NY, July 28th, 2022 – Palladium Capital Group, LLC, today announces that it has served as investment banker to Cryptyde (NASDAQ: TYDE) in restructuring some of its financing.

For details see the full 8-K filling here:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001892492/000149315222020485/form8-k.htm

Palladium Brokers Sale/Lease Back Financing for Aventine Property Group and Ayr Wellness (CNSX:AYR.A)

Post Date: Jun. 1, 2022

For more about Aventine Property Group, see here.

For more about AYR Wellness, see here.

Palladium Capital Group Advisor to Everflow on its sale to Pegasystems Inc. (NASDAQ: PEGA)

Post Date: May. 24, 2022

NEW YORK, NY – May 24, 2022, Palladium Capital Group, LLC (“Palladium”) announced today that it served as advisor to Everflow Software Ltda. (“Everflow”) in its acquisition by Pegasystems Inc. (NASDAQ: PEGA), the software company that crushes business complexity. Everflow, is an innovative process mining software company based in Brazil. Everflow’s highly intuitive software will enable Pega clients to uncover and fix hidden process inefficiencies that often bog down organizational operations. Combined with Pega’s market-leading AI-powered decisioning and workflow automation capabilities, this acquisition will help Pega deliver the most complete hyperautomation solution available for enterprises.

As business complexity continues to rise, process mining has emerged as a critical tool to help organizations streamline bloated and inconsistent processes that slow employee productivity and ultimately harm the bottom line. But two major limitations hold back process mining’s full potential: first, most process mining tools are too difficult to use and are understood only by technical business consultants; second, process mining by itself can’t fix process problems, it can only identify where those problems lie and suggest possible work arounds.

Everflow will provide Pega clients with an easy-to-use process mining solution that allows businesspeople to analyze and optimize their customer and employee-related processes. It makes it simple for users to automatically model their real-world processes based on organizational activity logs. Then the software analyzes where those processes break down in the field and suggests ways to improve the approach. For example, a retail banking head may deploy Everflow to determine if customers are abandoning the bank’s mobile app when it takes too many clicks to complete a transaction, or an insurance executive may discover if back-office bottlenecks in the application approval workflow are slowing their underwriters down.

But the true power of Everflow’s elegant solution will be fully unlocked when combined with Pega’s market-leading platform for AI-powered decisioning and workflow automation – where these processes already live for many of the world’s leading organizations. When integrated, the solution will help Pega clients continuously monitor processes across the enterprise, identify process issues or deviations when they arise, and even fix them on the fly. This will evolve the process mining field beyond static modeling and deliver real-time process optimization, deploying true hyperautomation on an enterprise scale to improve operations and customer experiences.

The new process mining capability is expected to be available for Pega clients on a limited basis in Q4 this year and with general availability early next year. It will be offered as an add-on capability to Pega Process AI™ – a set of Pega Platform™ capabilities introduced last year that uses self-optimizing AI and decision management to help businesses improve their operations in real time. Terms of the deal were not disclosed.

The news will be announced today at Pega’s flagship event, PegaWorld iNspire, which is available online on Tuesday, May 24, in the Americas and Europe or Wednesday, May 25, for Asia Pacific and on replays thereafter. After the keynotes, join the Supercharge Your Pega Workflows with Process Mining and Process AI session to learn more about how Pega plans to bring process mining and AI together to deliver the most complete hyperautomation solution available.

For more information, visit www.pega.com/products/platform/process-mining .

Quotes & Commentary:

“Our acquisition of Everflow puts Pega in a position to fulfill the promise of hyperautomation like no other company in the industry,” said Alan Trefler, founder and CEO, Pega. “When combined with our intelligent low-code platform, Everflow will help Pega root out business process inefficiencies from end to end in even the largest and most complex enterprises. We know that digital transformation never stops, and this unique and powerful software combination will allow for continuous improvement in a time of continuous change.”

“We built Everflow solutions to make the power of process mining accessible and actionable for anyone to use,” said Kleber Stroeh, former CEO of Everflow and now current vice president, process mining, Pega. “This philosophy fits perfectly with Pega’s mission to crush business complexity by democratizing the tools that help organizations operate at their full potential. We look forward to joining with Pega and using our solution to help solve problems for some of the most important businesses in the world.”

Supporting Resources:

About Pegasystems
Pega delivers innovative software that crushes business complexity so our clients can make better decisions and get work done. We help the world’s leading brands solve their biggest business challenges: maximizing customer lifetime value, streamlining customer service, and boosting operational efficiency. Pega technology is powered by real-time AI and intelligent automation, while our scalable architecture and low-code platform help enterprises adapt to rapid change and transform for tomorrow. For more information, please visit www.pega.com.

Press Contact:
Sean Audet
Pegasystems Inc.              
sean.audet@pega.com 
(617) 528-5230
Twitter: @pega

All trademarks are the property of their respective owners.

SOURCE Pegasystems Inc.

Palladium Capital Group Serves as Financial Advisor to Enveric Biosciences (NASDAQ: ENVB) in Their Plans to Spin-off Cannabinoid Pipeline

Post Date: May. 11, 2022

New York, NY, May 11, 2022 – Palladium Capital Group, LLC today announced that it served as financial advisor to Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”) in the following anticipated transaction. Enveric, a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced plans to transfer and spin-off its cannabinoid clinical development pipeline assets to a wholly-owned subsidiary, Acanna Therapeutics Inc. (“Acanna”), by way of dividend to Enveric shareholders. The spin-off transaction will be subject to various conditions, including Acanna meeting the qualifications for listing on The Nasdaq Stock Market, and if successful, would result in two standalone public companies.

Dr. Joseph Tucker, CEO of Enveric Biosciences, commented, “In these challenging markets, the Board and Management team have spent considerable time evaluating the best way to create additional value for all stakeholders – patients, shareholders, and employees. We believe it would be in the best interest of our shareholders to spin-off 100% equity ownership of our cannabinoid clinical development pipeline. Upon completion of the proposed transaction, each resulting public company would be able to focus all its resources on the development of its respective pipeline assets, enabling, we anticipate, greater opportunity for product development success.”

Acanna has secured an initial $1MM from an investor in a Series A Convertible Preferred Stock and Warrant financing. Under the terms of the investment, Acanna will, subject to certain other conditions, receive an additional $4MM upon completion of the spin-off into an independent, separately traded public company listed on The Nasdaq Stock Market. Following the spin-off and the investment of an aggregate of $5MM, that investor is expected to hold 25% of Acanna and warrants to acquire additional shares. Palladium Capital Group acted as a financial advisor to Enveric. Please see the Current Report on Form 8-K filed by Enveric on May 11, 2022, for further details.

Dr. Tucker continued, “For Enveric and Acanna, this spin-off transaction would allow each company to commit 100% of its efforts and capabilities towards developing its respective drug candidate portfolio. For Enveric, going forward, we intend to focus on mental health. We believe that Enveric’s achievements in the last year, including preparations for a clinical trial, positive preclinical data, and ongoing expansion of our drug candidate portfolio, the Psybrary™, position us well for the future.”

Strategic Rationale for Spinoff
The Company believes that spinning off the cannabinoid assets will allow Enveric and Acanna to maximize long-term value for all stakeholders. Following the proposed transaction, both Enveric and Acanna intend to:

Have separate, focused management teams with the knowledge and skills to deploy appropriate strategies and meet the unique requirements for each company’s operations.
Allocate capital more efficiently and strategically to develop their respective assets further.
Provide unique investment characteristics of interest to the capital markets.

About Enveric Biosciences
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines. Enveric’s robust pipeline supports drug development from the clinic to commercialization aimed to help millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD, and more. For additional information, please visit www.enveric.com.

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,”” expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of not purely historical statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of the company to successfully spin-off its cannabinoid assets; the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com

Media Contacts
Natalie Dolphin
Enveric Biosciences Inc.
416.706.6364
ndolphin@enveric.com

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability to achieve the value creation contemplated by technical developments; the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Palladium Capital Group Facilitates $15,000,000 Convertible Preferred for Gozio Health

Post Date: Apr. 29, 2022

NEW YORK, NY, March April 29th, 2022 – Palladium Capital Group, LLC, today announces that it has served as the sole placement agent to Gozio Health in its $15,000,000 Series A Convertible Round from funds managed by Morgan Stanley Expansion Capital. The investment round will be used to accelerate Gozio’s growth and sets the stage for a long-term financial partnership.

“We are at a turning point in healthcare where digital strategy is not only a competitive differentiator for health systems but is foundational to positive consumer experiences. An effective digital platform can enhance engagement with patients, prevent revenue leakage and increase overall patient satisfaction,” said Joshua Titus, Founder and CEO of Gozio. “With the strong support of Morgan Stanley, Gozio is poised to substantially ramp up efforts to equip health systems with the kind of robust, extensible platform needed to optimize digital engagement.”

Gozio’s mobile patient engagement solution provides health systems with a turnkey digital front door, offering a unified platform which integrates HCIT applications, including physician directories, appointment scheduling, EHR and patient record access, into an easy-to-use mobile application. Gozio’s solution also leverages the Company’s patented, industry-leading wayfinding technology to provide real-time, turn-by-turn directions to patients and staff.

“The consumerization of healthcare is driving hospitals and health systems to increasingly focus on patient experience and engagement. Gozio offers a solution that helps patients not only navigate the physical network of the health system, but also provides patients mobile access to the services, information and applications necessary to engage patients in their own care,” said Melissa Daniels, Managing Director at Morgan Stanley Expansion Capital. “We believe Gozio’s digital front door and wayfinding technology provide a compelling value proposition by enhancing the personal end-to-end consumer experience within the network of the health system. We are thrilled to be partnering with Joshua and the Gozio team to support the Company as it continues on its growth trajectory.”

Gozio will use the funding to expand its client base among leading health systems, grow its client services and engineering teams, and advance the extensibility of its platform to support a digital health ecosystem.

About Gozio Health

Gozio Health offers an end-to-end, customizable digital health platform exclusively for healthcare systems. Gozio’s extensible mobile platform enables seamless consumer interactions and provides an anytime, anywhere connection to patients that improves their overall experience and access to care. Popular patient engagement features include patented indoor wayfinding with turn-by-turn navigation, virtual visits, physician directories, appointment scheduling, access to electronic health records, Urgent Care and Emergency Department wait-times, and extensive analytics capabilities. Gozio customers surveyed in a 2021 KLAS Research Emerging Technology Spotlight report found 100% satisfaction and improved experience for patients and staff. For more information, watch the video or visit www.goziohealth.com or find Gozio Health on Twitter and LinkedIn.

About Morgan Stanley Expansion Capital

Morgan Stanley Expansion Capital is the growth-focused private investment platform within Morgan Stanley Investment Management. Morgan Stanley Expansion Capital targets growth equity and credit investments within technology, healthcare, consumer, digital media and other high-growth sectors. For over three decades, Morgan Stanley Expansion Capital has successfully pursued growth investment opportunities and has completed investments in over 200 companies, leveraging the global brand and network of Morgan Stanley. For further information about Morgan Stanley Expansion Capital, please visit www.morganstanley.com/im/expansioncapital.